Authors
Latest:
Impact of Telemedicine Use on Outpatient-Related CO2 Emissions: Estimate From a National CohortTelemedicine was associated with a monthly avoidance of greenhouse gas emissions equivalent to the emissions of 61,255 to 130,076 passenger vehicles.
Latest:
CHAPTER 3. Guideline for Detection and Management of Diabetes in PregnancyFrom the Adult Diabetes and Clinical Research sections, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts
Latest:
Automating Care Quality Measurement With Health Information TechnologyThe authors discuss the design and evaluation of a health information technology platform that enables comprehensive, automated assessment of care quality in electronic medical records.
Latest:
Characteristics and Medication Use of Veterans in Medicare Advantage PlansVeterans enrolled in Medicare Advantage plans differed from fee-for-service sector enrollees in several demographic, geographic, and clinical characteristics and in patterns of medication use.
Latest:
Understanding Factors Associated With Increases in Medicare Advantage Enrollment, 2007-2018Increases in Medicare Advantage market share over the past 10 years are largely caused by an increased preference for managed care among Medicare beneficiaries.
Latest:
The Diagnosis for Diagnostics: Changes to Medicare Payment and Coverage of Clinical Laboratory TestsThe basis for determining Medicare payment rates for clinical diagnostic laboratory tests is changing. These changes will be important for all payers and providers to follow for future reimbursement and contract negotiations.
Latest:
Moving Pharma Contracting Into the Era of AccountabilityA chief medical officer for a major payer outlines the challenges making sure that certain high-cost therapies are directed to the patients who need them.
Latest:
Small Practice Participation and Performance in Medicare Accountable Care OrganizationsMedicare beneficiaries attributed to small practices in accountable care organizations (ACOs) achieve greater savings than beneficiaries attributed to large practices in ACOs.
Latest:
COPD Exacerbation Costs in the IMPACT Study: A Within-Trial AnalysisTreatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.
